Showing results (1-10 of 25) with videos related to
Sort By:
Pageof 3
European Journal of Medicinal Chemistry|June 6, 2020
Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discoveryDailin Liang, Yifan Yu, Zonghui MaDrug Discovery Today|September 21, 2023
RIPTACs: A groundbreaking approach to drug discoveryZonghui Ma, Andrew A Bolinger, Jia ZhouOcular Immunology and Inflammation|June 1, 2026
Comparison of Intraocular Inflammation Associated with High-Dose Intravitreal Anti-Vascular Endothelial Growth Factor Agents: A Real-World Disproportionality AnalysisJiantong Du, Chen Xing, Zonghui Ma, et al.ACS Medicinal Chemistry Letters|February 21, 2019
Development of Novel Anticancer Agents with a Scaffold of Tetrahydropyrido[4,3-<i>d</i>]pyrimidine-2,4-dioneZonghui Ma, Ge Gao, Kunsen Fang, et al.European Journal of Medicinal Chemistry|March 2, 2021
Specific non-genetic IAP-based protein erasers (SNIPERs) as a potential therapeutic strategyZonghui Ma, Yu Ji, Yifan Yu, et al.Children (Basel, Switzerland)|February 27, 2026
Drugs Associated with Pediatric Cataracts: A Real-World Pharmacovigilance StudyJiantong Du, Chen Xing, Zhiyue Zhang, et al.European Journal of Ophthalmology|May 6, 2026
Five year of post-marketing safety of teprotumumab: A disproportionality analysis of the FDA adverse event reporting systemJiantong Du, Chen Xing, Zhiyue Zhang, et al.Expert Opinion on Therapeutic Targets|January 30, 2023
Bromodomain-containing protein 4 (BRD4): a key player in inflammatory bowel disease and potential to inspire epigenetic therapeuticsZonghui Ma, Andrew A Bolinger, Jia Zhou, et al.Journal of Medicinal Chemistry|August 14, 2023
Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2)Zonghui Ma, Andrew A Bolinger, Haiying Chen, et al.Expert Opinion on Therapeutic Patents|September 2, 2024
An updated patent review of BRD4 degradersZonghui Ma, Cun Zhang, Andrew A Bolinger, et al.Pageof 3